OXFORD, England, July 29 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company), announced today the UK launch of the latest BD Nexiva(TM) Closed IV Catheter System designed to reduce healthcare workers' risk of needlestick injuries and minimise exposure to blood. The system includes the BD Q-SyteTM Luer Access Split Septum to help reduce catheter-related bloodstream infections (CRBSIs).
The new version of the BD Nexiva(TM) system introduces key developments, including: - New non-removable pinch clamp for easy, one-handed activation - Soft stabilisation platform designed to decrease catheter movement and associated complications, whilst providing greater patient comfort - New catheter grip design which accommodates the various insertion techniques employed by clinicians - Larger bore extension tubing on 18G and 20G cannulas for improved flow rates
Studies have shown that needlestick injuries are a significant risk to the physical and psychological health of nurses, and cause significant additional costs to healthcare provision(1).
Used for peripheral venous access, the all-in-one BD NexivaTM system is designed to reduce insertion attempts and limit healthcare workers' exposure to blood with its innovative blood-containment system that helps minimise blood leakage from the catheter hub. This safety-engineered system is also designed to reduce needlestick injury by using passive needle-shielding technology.
Studies in Europe have estimated that the associated costs of CRBSIs may be hundreds of millions of euros(2). An important feature incorporated into the BD Nexiva(TM) Closed IV Catheter System is the BD Q-SyteTM Luer Access Split Septum, which offers a straight and unobstructed fluid path, high flow rates, clear visibility and cleanability. A split septum needle access system has 64-70% lower CRBSI rates than mechanical valves(3). By eliminating the complexities of mechanical valves, this split-septum device helps reduce the number of places where bacteria may thrive(4). In fact, comparison studies found that patients are three times more likely, on average, to develop a CRBSI with mechanical valves versus a split-septum needle-less access system(2).
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit http://www.bd.com.
References 1 Royal College of Nursing, Needlestick Injury in 2008 2 E. Tacconelli, G. Smith, K. Hieke, A. Lafuma, P. Bastide. Epidemiology, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of four European countries: literature-and registry-based estimates. Journal 3 Rupp ME, Sholtz LA, Jourdan DR, et al. Outbreak of bloodstream infection temporally associated with the use of an intravascular needleless valve. CID. 2007;44:1408-1414 Salgado CD, Chinnes L, Paczesny TH, Cantey JR. Increased rate of catheter-related bloodstream infection associated with use of a needleless mechanical valve device at a long-term acute care hospital. Infect Control Hosp Epidemiol. 2007;28:684-688 4 Karchmer TB, Wood C, Ohl CA, et al. Contamination of mechanical valve needleless devices may contribute to catheter-related bloodstream infections. SHEA 2006 Presentation Number: 221 Poster Board Number: 47.
Contacts: Vikki Lomas, Corporate Communications, T: +44(0)1865-781607